DRKS00024706CompletedUnknown
A randomised, placebo-controlled, single blind, monocentric trial to investigate the influence of an artichoke leaf extract for the treatment of non-alcoholic fatty liver disease (NAFLD) - SteatoChoke
niversität des Saarlandes0 sites40 target enrollmentStarted: April 29, 2024Last updated:
Conditions
Trial Snapshot
- Phase
- Unknown
- Status
- Completed
- Sponsor
- Enrollment
- 40
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized controlled study
- Masking
- Blinded (masking used)
Eligibility Criteria
- Ages
- 18 Years to 65 Years (—)
- Sex
- All
Inclusion Criteria
- •1.Indication and decision for bariatric surgery (laparoscopic sleeve gastrectomy and laparoscopic Roux-en-Y gastric bypass)
- •2. BMI > 35 kg / m²
- •3. Age: 18 - 65 years
- •4. Ability to understand and sign the patient information and informed consent form
- •5. Written declaration of consent
Exclusion Criteria
- •1. Alcohol consumption> 30 g / d in men,> 20 g / d in women
- •2. Other treatment for an existing non-alcoholic fatty liver disease
- •3. Allergy to artichokes and / or other cork family
- •4. Acute biliary diseases
- •5. Acute hepatitis (exception NASH)
- •6. Pacemaker
- •8. Pregnant and breastfeeding women
- •9. Participation in an interventional clinical study that interferes with the primary endpoint
- •10. Lack of patient compliance
Investigators
Similar Trials
Active, not recruiting
Phase 1
A randomised, placebo-controlled, single-blind study to characterise the biomarker effects of the CSF-1 receptor antagonist JNJ-40346527 in participants with mild cognitive impairment.EUCTR2018-004149-17-GBniversity of Oxford / Clinical Trials and Research Governance54
Completed
Phase 2
Clinical study to evaluate the safety and efficacy of ATRICOV 452 for the treatment of COVID-19 along with the standard of care.CTRI/2021/01/030795Atrimed Pharmaceutical Pvt Ltd95
Active, not recruiting
Not Applicable
A single blind, placebo-controlled, randomised study in mild to moderate Alzheimer's disease patients to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK239512, a selective histamine H3 receptor antagonistAlzheimer's DiseaseEUCTR2007-004117-33-CZGlaxoSmithKline R&D Ltd38
Active, not recruiting
Not Applicable
A single blind, placebo-controlled, randomised study in mild to moderate Alzheimer's disease patients to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK239512, a selective histamine H3 receptor antagonistMedDRA version: 9.1Level: LLTClassification code 10001896Term: Alzheimer's diseaseAlzheimer's DiseaseEUCTR2007-004117-33-GBGlaxoSmithKline R&D Ltd38
Active, not recruiting
Not Applicable
A randomized, single-blind, placebo-controlled, parallel-group study evaluating the anti-inflammatory activity of GSK315234 in synovial biopsy tissue obtained from subjects with rheumatoid arthritisMedDRA version: 12.1Level: LLTClassification code 10039073Term: Rheumatoid arthritisRheumatoid arthritisEUCTR2009-012055-19-IEGlaxoSmithKline Research & Development Limited45